Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginfast PRL is a dietary supplement (nutraceutical) developed by Logus Pharma, specifically formulated to manage hyperprolactinemia and associated conditions such as premenstrual syndrome (PMS) and menstrual cycle irregularities. The primary active component is *Vitex agnus-castus* (chasteberry) extract, which contains dopaminergic compounds that bind to dopamine D2 receptors in the anterior pituitary. This binding inhibits the release of prolactin, thereby helping to normalize the progesterone-to-estrogen ratio and alleviate symptoms related to hormonal imbalance. It is often supplemented with Vitamin B6 (pyridoxine), Zinc, and Vitamin E to support reproductive health and hormonal regulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ginfast PRL.